# Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression

> **NCT00518986** · PHASE4 · COMPLETED · sponsor: **Cephalon** · enrollment: 249 (actual)

## Conditions studied

- Sleep Disorders
- Obstructive Sleep Apnea
- Major Depressive Disorder
- Dysthymic Disorder

## Interventions

- **DRUG:** armodafinil
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00518986
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2013-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00518986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00518986, "Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00518986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*